Published in Oncotarget on September 29, 2015
Targeting Stromal-Cancer Cell Crosstalk Networks in Ovarian Cancer Treatment. Biomolecules (2016) 0.80
Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer. BMC Syst Biol (2016) 0.77
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell (2009) 16.06
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell (2009) 13.09
Ovarian cancer. Lancet (2014) 3.80
Prognostic value of CA 125 in advanced ovarian cancer. Gynecol Oncol (1992) 2.72
Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst (1995) 2.44
Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol (2005) 2.34
Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer (1997) 2.20
Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem (2001) 2.15
Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer (2011) 2.09
Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res (1996) 1.94
Pathology and classification of ovarian tumors. Cancer (2003) 1.90
Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer (1996) 1.84
History of the FIGO cancer staging system. Int J Gynaecol Obstet (2008) 1.81
Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology (1998) 1.61
Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res (2002) 1.57
Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol (1999) 1.54
Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer (2000) 1.51
Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies? Clin Cancer Res (2008) 1.46
Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol (2006) 1.42
Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev (2012) 1.31
Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem (2004) 1.27
Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Res (2004) 1.24
VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecol Oncol (2004) 1.22
Gynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology. Gynecol Oncol (2014) 1.19
The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma. Mol Cell Endocrinol (2002) 1.16
Angiogenesis in normal and neoplastic ovaries. Angiogenesis (2005) 1.16
Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett (1997) 1.13
Ovarian cancer biomarkers for molecular biosensors and translational medicine. Expert Rev Mol Diagn (2010) 1.12
Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist (2000) 1.06
Angiogenic protein expression in advanced epithelial ovarian cancer. Clin Cancer Res (1997) 1.06
Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma. Int J Gynecol Cancer (2004) 1.06
Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. Clin Cancer Res (2006) 1.05
VEGF and HIF-1alpha expression are increased in advanced stages of epithelial ovarian cancer. Gynecol Oncol (2003) 1.05
Basic fibroblast growth factor and receptor expression in human ovarian cancer. Gynecol Oncol (1994) 1.04
Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors. Pharm Res (2006) 1.03
Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Crit Rev Oncol Hematol (2008) 1.01
From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer. Int J Cancer (2006) 1.01
Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clin Cancer Res (2010) 0.99
Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review. J Ovarian Res (2014) 0.98
Modulation of angiogenic phenotype alters tumorigenicity in rat ovarian epithelial cells. Cancer Res (2007) 0.96
The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer. Clin Cancer Res (2005) 0.93
Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol (2007) 0.92
Prognostic significance of intratumoral vascular endothelial growth factor as a marker of tumour angiogenesis in epithelial ovarian cancer. Eur J Gynaecol Oncol (2010) 0.89
CA125 (MUC16) gene silencing suppresses growth properties of ovarian and breast cancer cells. Eur J Cancer (2011) 0.89
Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer. Int J Gynecol Cancer (2009) 0.89
Vascular endothelial growth factor expression in ovarian serous carcinomas and its effect on tumor proliferation. South Asian J Cancer (2013) 0.89
Influence of intratumoral basic fibroblast growth factor concentration on survival in ovarian cancer patients. Cancer Lett (1998) 0.87
HN125: A Novel Immunoadhesin Targeting MUC16 with Potential for Cancer Therapy. J Cancer (2011) 0.86
Association of vascular endothelial growth factor expression with tumor cell proliferation in ovarian carcinoma. Anticancer Res (1997) 0.85
Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer. Angiogenesis (2011) 0.85
Vascular endothelial growth factor inhibition: conflicting roles in tumor growth. Cytokine (2010) 0.85
Sprouty 2 protein, but not Sprouty 4, is an independent prognostic biomarker for human epithelial ovarian cancer. Int J Cancer (2015) 0.84
Expression of basic fibroblast growth factor and its mRNA in advanced ovarian cancers. Eur J Gynaecol Oncol (1997) 0.84
Possible use of CA-125 level normalization after the third chemotherapy cycle in deciding on chemotherapy regimen in patients with epithelial ovarian cancer: brief report. Int J Gynecol Cancer (2011) 0.80
VEGF-D-induced draining lymphatic enlargement and tumor lymphangiogenesis promote lymph node metastasis in a xenograft model of ovarian carcinoma. Reprod Biol Endocrinol (2014) 0.80
CA 125 and vascular endothelial growth factor in the differential diagnosis of epithelial ovarian tumors. Gynecol Obstet Invest (2002) 0.80
[Expression of aFGF and bFGF in ovarian cancer and their effect on ovarian cancer cell proliferation]. Ai Zheng (2003) 0.78
[The effect of basic fibroblast growth factor in ovarian cancer growth and angiogenesis]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi (2003) 0.78
[An experimental research in the inhibiting effect of bFGF-MAb on the growth of ovarian cancer cells and transplanted tumor]. Sichuan Da Xue Xue Bao Yi Xue Ban (2003) 0.77